PMID: 10618609Jan 5, 2000Paper

Paclitaxel and tamoxifen: An active regimen for patients with metastatic melanoma

Cancer
F E NathanM J Mastrangelo

Abstract

In early trials of paclitaxel administered as a 24-hour infusion, an overall response rate of 16% was reported for patients with metastatic melanoma. Paclitaxel is a natural product-based agent and is thus subject to the problem of multidrug resistance (MDR). Tamoxifen is an agent that can abrogate MDR and potentially enhance the effect of paclitaxel. A Phase II trial of the combination was undertaken with previously treated patients. Patients with metastatic cutaneous or mucosal melanoma who were previously treated with the Dartmouth chemotherapy regimen (dacarbazine, carmustine, cisplatin, and tamoxifen) were evaluated. Paclitaxel was administered at a dose of 225 mg/m(2) intravenously over 3 hours every 3 weeks. All patients also took tamoxifen 40 mg orally daily. Treatment continued until disease progression. Twenty-one patients completed at least two cycles of paclitaxel and were evaluable for response. Five responses were observed, 1 complete response, and 4 partial responses, for an overall response rate of 24%. The combination was well tolerated. The most common nonhematologic side effects were myalgia and paresthesia. Hematologic toxicity was mild. No patients developed neutropenic fever. This is the first report of a ...Continue Reading

References

Jan 1, 1992·European Journal of Cancer : Official Journal for European Organization for Research and Treatment of Cancer (EORTC) [and] European Association for Cancer Research (EACR)·M J MillwardA L Harris
Feb 1, 1991·Investigational New Drugs·A EinzigT J Smith
Jul 1, 1991·Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology·T BrownD Von Hoff
Jun 1, 1990·Cancer·S S LeghaR S Benjamin
Dec 1, 1990·Cancer Treatment Reviews·S B Kaye
Sep 1, 1989·Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology·M W DeGregorioV J Wiebe
Aug 1, 1987·Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology·P H WiernikJ P Dutcher
Aug 1, 1994·Leukemia & Lymphoma·P L ZinzaniS Tura
Dec 1, 1994·Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology·E A EisenhauerN Colombo
Nov 4, 1996·International Journal of Cancer. Journal International Du Cancer·R De VincenzoS Mancuso
May 20, 1998·Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology·S S LeghaN Papadopoulos

Citations

Nov 6, 2002·The Journal of Clinical Investigation·Stephan FellnerGert Fricker
Oct 24, 2000·Clinical and Experimental Dermatology·J C BeckerE Bröcker
Nov 5, 2014·Journal of Medicinal Chemistry·Niamh M O'BoyleMary J Meegan
Apr 25, 2006·Surgical Oncology Clinics of North America·Steven O'Day, Peter Boasberg
Jul 24, 2004·The British Journal of Dermatology·E RichtigJ Smolle
May 29, 2003·Journal of Surgical Oncology·Jesus E MedinaAlessandra Rinaldo
Dec 18, 2007·Seminars in Oncology·Hussein A Tawbi, John M Kirkwood
Jul 15, 2015·European Journal of Pharmacology·Mariana P C RibeiroJosé B A Custódio
May 13, 2015·Biochimica Et Biophysica Acta·Samy A F Morad, Myles C Cabot
Oct 15, 2009·Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology·Steven O'DayEric Jacobson
Oct 1, 2004·Melanoma Research·Helen GogasAgop Y Bedikian
Jun 6, 2007·Doklady. Biochemistry and Biophysics·E A BogushM I Davydov
Nov 30, 2019·Journal of Cellular and Molecular Medicine·Shuai HuangJian Wang
Jun 9, 2021·Journal of Medicinal Chemistry·Wen ShuaiYuxi Wang

Related Concepts

Related Feeds

Birth Defects

Birth defects encompass structural and functional alterations that occur during embryonic or fetal development and are present since birth. The cause may be genetic, environmental or unknown and can result in physical and/or mental impairment. Here is the latest research on birth defects.